Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: A 'real-world' retrospective study.

Javier Peña-CeballosPatrick B MoloneyTudor MunteanuMichael DoyleNiamh ColleranBrenda LigganAnnette BreenSinead MurphyHany El-NaggarPeter Widdess-WalshNorman Delanty

Published in: Epilepsia (2023)

Patients with highly active and ultra-refractory focal epilepsy experienced meaningful seizure outcomes on cenobamate. Emergence of adverse events at doses above 250mg/day may limit the potential for further improvements in seizure control at higher cenobamate doses.

Keyphrases

temporal lobe epilepsy
high resolution
metabolic syndrome
human health
climate change